De­spite Phase 3 win, Roche says rare au­toim­mune drug did­n't meet ex­pec­ta­tions

Roche’s Chugai Phar­ma­ceu­ti­cal said its im­mune dis­ease drug En­spryng didn’t pro­duce the re­sults it was hop­ing for in a Phase 3 study in gen­er­al­ized myas­the­nia gravis, an au­toim­mune dis­or­der that leads to weak­ness in vol­un­tary mus­cles.

En­spryng hit the pri­ma­ry end­point of the study, which mea­sured change on a scale of the dis­or­der’s im­pact on dai­ly func­tions at 24 weeks. But “the re­sults did not reach our ex­pec­ta­tions on the de­gree of clin­i­cal ben­e­fit,” Chugai said Thurs­day in a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.